» Articles » PMID: 31906300

Targeted Polymer-Based Probes for Fluorescence Guided Visualization and Potential Surgery of EGFR-Positive Head-and-Neck Tumors

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2020 Jan 8
PMID 31906300
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

This report describes the design, synthesis and evaluation of tumor-targeted polymer probes to visualize epidermal growth factor receptor (EGFR)-positive malignant tumors for successful resection via fluorescence guided endoscopic surgery. Fluorescent polymer probes of various molecular weights enabling passive accumulation in tumors via enhanced permeability and retention were prepared and evaluated, showing an optimal molecular weight of 200,000 g/mol for passive tumor targeting. Moreover, poly(-(2-hydroxypropyl)methacrylamide)-based copolymers labeled with fluorescent dyes were targeted with the EGFR-binding oligopeptide GE-11 (YHWYGYTPQNVI), human EGF or anti-EGFR monoclonal antibody cetuximab were all able to actively target the surface of EGFR-positive tumor cells. Nanoprobes targeted with GE-11 and cetuximab showed the best targeting profile but differed in their tumor accumulation kinetics. Cetuximab increased tumor accumulation after 15 min, whereas GE 11 needed at least 4 h. Interestingly, after 4 h, there were no significant differences in tumor targeting, indicating the potential of oligopeptide targeting for fluorescence-navigated surgery. In conclusion, fluorescent polymer probes targeted by oligopeptide GE-11 or whole antibody are excellent tools for surgical navigation during oncological surgery of head and neck squamous cell carcinoma, due to their relatively simple design, synthesis and cost, as well as optimal pharmacokinetics and accumulation in tumors.

Citing Articles

Recent advances of photodiagnosis and treatment for head and neck squamous cell carcinoma.

Zhang Y, Li Z, Zhang C, Shao C, Duan Y, Zheng G Neoplasia. 2024; 60:101118.

PMID: 39721461 PMC: 11732236. DOI: 10.1016/j.neo.2024.101118.


Application of Intelligent Response Fluorescent Probe in Breast Cancer.

Sheng A, Zhang H, Li Q, Chen S, Wang Q Molecules. 2024; 29(18).

PMID: 39339288 PMC: 11434508. DOI: 10.3390/molecules29184294.


"All in one" nanoprobe Au-TTF-1 for target FL/CT bioimaging, machine learning technology and imaging-guided photothermal therapy against lung adenocarcinoma.

Yang Z, Zhang Y, Tang L, Yang X, Song L, Shen C J Nanobiotechnology. 2024; 22(1):22.

PMID: 38184620 PMC: 10770976. DOI: 10.1186/s12951-023-02280-9.


Effect of the Size and Shape of Dendronized Iron Oxide Nanoparticles Bearing a Targeting Ligand on MRI, Magnetic Hyperthermia, and Photothermia Properties-From Suspension to In Vitro Studies.

Freis B, Ramirez M, Kiefer C, Harlepp S, Iacovita C, Henoumont C Pharmaceutics. 2023; 15(4).

PMID: 37111590 PMC: 10143744. DOI: 10.3390/pharmaceutics15041104.


Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases.

Talamini L, Matsuura E, De Cola L, Muller S Cells. 2021; 10(3).

PMID: 33806746 PMC: 8004653. DOI: 10.3390/cells10030707.


References
1.
Xu H, Zong H, Ma C, Ming X, Shang M, Li K . Epidermal growth factor receptor in glioblastoma. Oncol Lett. 2017; 14(1):512-516. PMC: 5494611. DOI: 10.3892/ol.2017.6221. View

2.
Ali R, Wendt M . The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther. 2017; 2. PMC: 5397119. DOI: 10.1038/sigtrans.2016.42. View

3.
Zimmermann M, Zouhair A, Azria D, Ozsahin M . The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006; 1:11. PMC: 1524965. DOI: 10.1186/1748-717X-1-11. View

4.
Huang L, Gainkam L, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P . SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008; 10(3):167-75. DOI: 10.1007/s11307-008-0133-8. View

5.
Orcutt K, Parsons A, Sibenaller Z, Scarbrough P, Zhu Y, Sobhakumari A . Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer Res. 2011; 71(11):3932-40. PMC: 3217301. DOI: 10.1158/0008-5472.CAN-10-3425. View